202 related articles for article (PubMed ID: 38268596)
1. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
2. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
3. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
5. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
Busse W; Chupp G; Nagase H; Albers FC; Doyle S; Shen Q; Bratton DJ; Gunsoy NB
J Allergy Clin Immunol; 2019 Jan; 143(1):190-200.e20. PubMed ID: 30205189
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
7. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.
Edris A; De Feyter S; Maes T; Joos G; Lahousse L
Respir Res; 2019 Aug; 20(1):179. PubMed ID: 31395084
[TBL] [Abstract][Full Text] [Related]
9. Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis.
Liu W; Ma X; Zhou W
Medicine (Baltimore); 2019 May; 98(22):e15868. PubMed ID: 31145343
[TBL] [Abstract][Full Text] [Related]
10. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Akenroye A; Lassiter G; Jackson JW; Keet C; Segal J; Alexander GC; Hong H
J Allergy Clin Immunol; 2022 Nov; 150(5):1097-1105.e12. PubMed ID: 35772597
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis.
Henriksen DP; Bodtger U; Sidenius K; Maltbaek N; Pedersen L; Madsen H; Andersson EA; Norgaard O; Madsen LK; Chawes BL
Eur Clin Respir J; 2018; 5(1):1536097. PubMed ID: 30533206
[No Abstract] [Full Text] [Related]
13. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.
Charles D; Shanley J; Temple SN; Rattu A; Khaleva E; Roberts G
Clin Exp Allergy; 2022 May; 52(5):616-627. PubMed ID: 35174566
[TBL] [Abstract][Full Text] [Related]
14. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
[TBL] [Abstract][Full Text] [Related]
15. Role of eosinophilic chronic rhinosinusitis in switching to benralizumab treatment in mepolizumab responders.
Hamada S; Kobayashi Y; Yasuba H
Int J Clin Pharmacol Ther; 2020 Dec; 58(12):703-708. PubMed ID: 32831163
[TBL] [Abstract][Full Text] [Related]
16. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
[TBL] [Abstract][Full Text] [Related]
17. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
18. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Castro M; Wenzel SE; Bleecker ER; Pizzichini E; Kuna P; Busse WW; Gossage DL; Ward CK; Wu Y; Wang B; Khatry DB; van der Merwe R; Kolbeck R; Molfino NA; Raible DG
Lancet Respir Med; 2014 Nov; 2(11):879-890. PubMed ID: 25306557
[TBL] [Abstract][Full Text] [Related]
19. Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments.
Li W; Tang SC; Jin L
BMC Pulm Med; 2024 Feb; 24(1):70. PubMed ID: 38308249
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Anti-Interleukin-5 Therapies in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Wang Q; Sun Q; Chen Q; Li H; Liu D; Wu Q
Int Arch Allergy Immunol; 2022; 183(7):732-743. PubMed ID: 35108711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]